Overview

Clinical Study to Evaluate the Possible Efficacy of Dapagliflozin and Atorvastatin in Patients With Major Depressive Disorders

Status:
Not yet recruiting
Trial end date:
2025-03-20
Target enrollment:
0
Participant gender:
All
Summary
Major depressive disorder (MDD) is a significant cause of disability that affects approximately 16% of the world's population and is associated with chronic inflammation. Although the mechanisms of MDD have not yet been clearly elucidated, NLRP3 inflammasomes have been implicated in the pathogenesis of depression.NLRP3 inflammasome is an intracellular multiprotein complex that consists of nod-like receptor protein 3, an adaptor protein, and a procaspase-1 precursor. It is well known that a variety of danger signals, such as pathogen-associated molecular patterns and danger-associated molecular patterns can activate NLRP3 inflammasome
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Tanta University
Collaborators:
Eman Ibrahim Elberri, Faculty of Pharmacy, Tanta University
Fedaa Abd El-monem Kamal El-deen Kotkata Faculty of Pharmacy, Tanta University
Manal Ali Mahrous Hamouda Faculty of Pharmacy, Menufia University
Treatments:
Atorvastatin
Dapagliflozin
Fluoxetine
Criteria
Inclusion Criteria:

- Age ≥ 18 years Both males and females will be included Negative pregnancy test and
effective contraception. Depressed patients for at least 2 months with a Hamilton rating
score of more than 18.

Exclusion Criteria:

- Patients with bipolar I or bipolar II disorder

- Patients with personality disorders

- Patients with eating disorders

- Patients with substance dependence or abuse

- Patients with concurrent active medical conditions

- Patients with a history of seizures

- Patients with a history of receiving Electroconvulsive therapy (ECT)

- Patients with inflammatory disorders

- Patients with allergies or contraindications to the used medications

- Patients with finally pregnant or lactating females

- Diabetic or hyperlipidaemic patients